23:43 , Jan 14, 2019 |  BC Extra  |  Politics & Policy

House begins campaign to publicize and politicize drug pricing

Requests for pricing and cost information sent Monday by the House Oversight and Reform Committee to a dozen biopharma companies mark the start of what is certain to be a sustained campaign by House Democrats...
01:15 , Jan 12, 2019 |  BioCentury  |  Finance

JPM jump-starts 2019

About three quarters of the more than 200 biopharma companies presenting at the 2019 J.P. Morgan Healthcare Conference saw their stock prices rise last week. Leading the pack was the 53% jump by Insmed Inc....
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech companies...
17:58 , Jan 11, 2019 |  BC Week In Review  |  Clinical News

Plinabulin meets in Phase III for chemotherapy-induced neutropenia

BeyondSpring Inc. (NASDAQ:BYSI) reported interim data on Dec. 6 showing that plinabulin (BPI-2358) met the primary endpoint in the Phase III portion of the Phase II/III Protective-1 trial to treat chemotherapy-induced neutropenia in patients with...
03:38 , Jan 11, 2019 |  BC Innovations  |  Product R&D

PureTech turns inward

After a 15-year run of spinning out technologies into affiliate companies, PureTech Health plc is stepping away from that model in favor of an internal pipeline to advance its new platforms. Behind the structural shift...
00:03 , Jan 11, 2019 |  BC Extra  |  Politics & Policy

Sanders, Democratic co-sponsors to reintroduce drug pricing bills

Sen. Bernie Sanders (I-Vt.) and Democratic co-sponsors plan to reintroduce legislation for Congress’ new term aimed at reducing drug prices through reference pricing, drug importation and Medicare Part D drug negotiation. The first bill ,...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
13:49 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) In vitro , cell culture, mouse and rat studies identified an inhibitor of internal tandem duplication (ITD)-mutant FLT3 that could help treat AML. Chemical synthesis and cell-based binding assays of...
13:43 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Endocrine/metabolic

INDICATION: Obesity Cell culture, mouse and non-human primate (NHP) studies suggest inhibiting the GIP receptor alone or in combination with GLP-1R agonists could help treat obesity. In a mouse model of diet-induced obesity, a mouse...
05:26 , Dec 22, 2018 |  BC Extra  |  Politics & Policy

Partial shutdown sees 41% of FDA staff furloughed

FDA has furloughed almost half its staff after the U.S. government partially shut down early Dec. 22, potentially slowing approvals and stalling advisory committee meetings. Commissioner Scott Gottlieb confirmed in a tweet Friday that FDA...